ahlam1399
07-22-2016, 05:27 AM
BRIEF-Resverlogix Corp an**unces dosing of first two patients in expanded renal and orphan programs
* Results are expected in second half of 2016 from phase 1studyhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=oRxT3ASqP6U:72CrXCR4yeM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=oRxT3ASqP6U:72CrXCR4yeM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=oRxT3ASqP6U:72CrXCR4yeM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=oRxT3ASqP6U:72CrXCR4yeM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=oRxT3ASqP6U:72CrXCR4yeM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/oRxT3ASqP6U
* Results are expected in second half of 2016 from phase 1studyhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=oRxT3ASqP6U:72CrXCR4yeM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=oRxT3ASqP6U:72CrXCR4yeM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=oRxT3ASqP6U:72CrXCR4yeM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=oRxT3ASqP6U:72CrXCR4yeM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=oRxT3ASqP6U:72CrXCR4yeM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/oRxT3ASqP6U